Wednesday

8th Feb 2023

EU silent on US buying up world's remdesivir supplies

The European Commission on Wednesday (1 July) refused to speak out against the US decision to buy up most of the world's stock of remdesivir.

The drug, manufactured by the US-based biopharmaceutical company Gilead, has been proven to work against Covid-19.

Read and decide

Join EUobserver today

Become an expert on Europe

Get instant access to all articles — and 20 years of archives. 14-day free trial.

... or subscribe as a group

Two of the most senior European Commission officials, vice-presidents Margaritis Schinas and Valdis Dombrovskis, declined to respond to questions on the US move during a press conference on Wednesday.

Instead, the European Commission's official spokesperson services in an email sent later in the day announced it had taken "note of the announcement made yesterday regarding doses available for the US."

The tiptoeing may be due to broader efforts by the Commission to negotiate with Gilead for reserve doses of remdesivir for EU member states.

"Given the confidentiality of these discussions, no details can be given at this stage," said European commission spokesperson, Stefan de Keersmaecker, in an emailed statement.

But with the US buying up three months of stocks, leaving Europe and most the world without, the commission's strategy to secure the drug is likely to pose some tricky questions.

The Trump administration bought more than 500,000 doses, spanning all of Gilead's production for July and throughout most of autumn.

Similar tactics by the Trump administration in March to acquire the exclusive rights to a vaccine being developed by CureVac, a German firm, were roundly condemned.

In May, the French government expressed outrage after the CEO of the French pharmaceutical giant Sanofi said the US would get first doses on any Covid-19 vaccine.

Meanwhile, Germany on Wednesday told Reuters news agency it had secured sufficient supplies of remdesivir.

"The federal government has early on secured remdesivir for the treatment of coronavirus patients. Currently, there are still sufficient reserves," Germany's health ministry told Reuters in a written statement.

The Amsterdam-based European Medicines Agency (EMA) had only last week recommended granting a conditional marketing authorisation for remdesivir.

The drug is the first and so far the only Covid-19 treatment recommended for EU authorisation.

"As of 15 June, EMA has been in contact with developers of 132 potential Covid-19 therapeutics and 34 potential vaccines," the EMA said in an email.

For its part, the commission says their decision to speed up the process to grant a marketing authorisation for remdesivir in the coming days, is a demonstration of their commitment to ensure that scientifically proven effective treatments for Covid-19 are available to EU citizens.

Analysis

Waking up after corona. How will the world look?

Many people hoped that after corona we would wake up in a friendlier world. Unfortunately, the opposite seems to be the case. A cocktail of several fears is fuelling the already existing trend of polarisation, worldwide.

Investigation

EU taxpayers in the dark on US corona-drug deal

The EU recently signed a huge contract for a US anti-corona drug which, the WHO says, might not work, but there's little transparency on how the deal was made.

Feature

Eleven suicides daily — Spain's not-so-silent pandemic

With the emergence of the pandemic, Spain's suicide figures have worsened, bringing to the surface the long waiting times, the lack of health personnel, and the absence of a national suicide prevention plan.

Analysis

MEPs push for greater powers for workers' councils

European Works Councils can play a key role for workers and their unions to bargain effectively — but what are they, why have they been neutered, and why is big business objecting to greater powers?

Analysis

MEPs push for greater powers for workers' councils

European Works Councils can play a key role for workers and their unions to bargain effectively — but what are they, why have they been neutered, and why is big business objecting to greater powers?

Latest News

  1. Polish MEP also went on freelance Azerbaijan trip
  2. Why Europe's interminable compromises are a virtue
  3. Wales' message to Europe: 'We'll be back'
  4. MEPs to vote on risky 'hydrogen for home heating' rule
  5. The man who won't stop filing info requests until every EU doc is public
  6. EU hands Libya coast guard boats ahead of migration summit
  7. Eleven suicides daily — Spain's not-so-silent pandemic
  8. The return of Lula means now is the time for EU-Mercosur deal

Stakeholders' Highlights

  1. EFBWWEU Social Dialogue review – publication of the European Commission package and joint statement of ETUFs
  2. Oxfam InternationalPan Africa Program Progress Report 2022 - Post Covid and Beyond
  3. WWFWWF Living Planet Report
  4. EFBWWEFBWW Executive Committee report on major abuses, labour crime and subcontracting
  5. European Parliamentary Forum for Sexual & Reproductive Rights (EPF)Launch of the EPF Contraception Policy Atlas Europe 2023. 8th February. Register now.
  6. Europan Patent OfficeHydrogen patents for a clean energy future: A global trend analysis of innovation along hydrogen value chains

Join EUobserver

Support quality EU news

Join us